Literature DB >> 2648838

Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.

S C Rubin1, W J Hoskins, T B Hakes, M Markman, B S Reichman, D Chapman, J L Lewis.   

Abstract

Serum CA 125 levels and surgical findings were prospectively compared in 96 secondary laparotomies performed on patients with epithelial ovarian cancer. All patients had documentation of an elevated CA 125 level (greater than 35 U/ml) at a time when ovarian cancer was present, and thus the tumors were known to be "marker positive." Operation was performed in 45 patients who were clinically free of disease and in 51 patients in whom there was clinical evidence of disease. At the time of operation, 29 patients had normal CA 125 levels; persistent disease was documented in 18 (62%) of these. Of the patients with normal CA 125 levels at the time of operation, those with persistent disease had a significantly higher mean CA 125 level (16.9) than those with no disease detected (8.8, p = 0.001). At exploration, cancer was found in 84 patients. There was a correlation between the maximum diameter of the largest residual tumor mass and the accuracy of the CA 125 level as follows: microscopic to 1 cm disease, 55% accuracy; greater than 1 to 5 cm disease, 80% accuracy; greater than 5 cm disease, 92% accuracy (p = 0.013). There was no correlation of CA 125 accuracy with the patient's age, number of months from initial diagnosis, tumor stage, grade, or cell type, or the highest-ever level of CA 125. Of the 84 patients with tumor found at exploration, 66 had elevated CA 125 levels, yielding a sensitivity of 78.5%. There were 12 patients with no tumor found at exploration; 11 of these had normal CA 125 levels. The one patient who had an elevated CA 125 level subsequently had a recurrence; the corrected specificity is thus 100%. An elevated CA 125 level is an accurate predictor of persistent disease. Most of these patients will have gross tumor present. The accuracy of the CA 125 level in detecting disease is related to the amount of tumor present. In our population, the predictive value of an elevated CA 125 level was 100%; the predictive value of a normal CA 125 level was 38%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2648838     DOI: 10.1016/s0002-9378(89)80054-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

Review 1.  Limitations to the use of the CA-125 antigen level in ovarian cancer.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

2.  Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.

Authors:  Munetaka Takekuma; Makoto Maeda; Takachika Ozawa; Kazuhiko Yasumi; Tatsuo Torizuka
Journal:  Int J Clin Oncol       Date:  2005-06       Impact factor: 3.402

3.  Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival.

Authors:  Evis Sala; Masako Kataoka; Neeta Pandit-Taskar; Nicole Ishill; Svetlana Mironov; Chaya S Moskowitz; Oleg Mironov; Michelle A Collins; Dennis S Chi; Steven Larson; Hedvig Hricak
Journal:  Radiology       Date:  2010-08-09       Impact factor: 11.105

4.  The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group.

Authors:  K Karrer; H Salzer; P Sevelda; C Dittrich
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

Authors:  Sven Mahner; Linn Woelber; Christine Eulenburg; Joerg Schwarz; Walter Carney; Fritz Jaenicke; Karin Milde-Langosch; Volkmar Mueller
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

6.  A novel human monoclonal antibody against cervical cancer: its immunoreactivity with normal tube and ovary and with ovarian tumor tissue.

Authors:  T Nakanishi; T Okamoto; A Nawa; T Suzuki; K Ino; Y Wakahara; N Horibe; S Goto; Y Tomoda
Journal:  Arch Gynecol Obstet       Date:  1995       Impact factor: 2.344

7.  CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

Authors:  Xiaoxiang Chen; Jing Zhang; Wenjun Cheng; Doo Young Chang; Jianfei Huang; Xuan Wang; Lizhou Jia; Daniel G Rosen; Wei Zhang; Da Yang; David M Gershenson; Anil K Sood; Robert C Bast; Jinsong Liu
Journal:  Int J Gynecol Cancer       Date:  2013-06       Impact factor: 3.437

8.  Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer.

Authors:  Shinichi Tate; Kyoko Nishikimi; Kazuyoshi Kato; Ayumu Matsuoka; Michiyo Kambe; Takako Kiyokawa; Makio Shozu
Journal:  J Gynecol Oncol       Date:  2019-12-09       Impact factor: 4.401

9.  Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers.

Authors:  H Kobayashi; H Ohi; T Fujii; T Terao
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

10.  Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer.

Authors:  Szymon Piatek; Grzegorz Panek; Zbigniew Lewandowski; Dominika Piatek; Przemyslaw Kosinski; Mariusz Bidzinski
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.